grant
Improving sarcopenia by targeting mitochondria
Organization OHIO STATE UNIVERSITYLocation Columbus, UNITED STATESPosted 5 Sept 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY202521+ years old9-Octadecenoic AcidATP SynthesisATP Synthesis PathwayAbdominal obesityAdultAdult HumanAffectAgeAgingAndroid fat distributionBaltimoreBloodBlood PlasmaBlood Reticuloendothelial SystemBody TissuesCardiolipinsCardiometabolic DiseaseCardiometabolic DisorderCentral obesityCentripetal obesityClinical TrialsDataDecline in mobilityDecrease in mobilityDecreased mobilityDevelopmentDietDietary biomarkersDietary intakeDiminished mobilityDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrugsDyslipidemiasElectron TransportEpidemiological dataEpidemiology dataEssential Fatty AcidsEventExerciseExtensorExtravasationFDA approvedFatigueFortificationGait speedH+ elementHealthHealth Care CostsHealth CostsHumanHydrogen IonsImmobilizationImpairmentInner mitochondrial membraneInsulin ResistanceIntakeIntramuscularIsokinetic ExerciseIsokineticsIsotonic ExerciseIsotonicsLack of EnergyLeakageLeannessLegLifestyle TherapyLinkLinoleic AcidsLongitudinal StudiesLysolecithinsLysophosphatidylcholinesMammaliaMammalsMeasuresMedicationMethodsMiceMice MammalsMitochondriaMobility declineMobility impairmentModern ManMorbidityMorbidity - disease rateMurineMusMuscleMuscle AtrophyMuscle TissueMuscle WeaknessMuscle functionMuscular AtrophyMuscular WeaknessN-3 polyunsaturated fatty acidNutritional RequirementsNutritional biomarkersOilsOlder PopulationOleic AcidsOmega-3 Fatty AcidsOmega-3 PUFAOmega-3 Polyunsaturated Fatty AcidOmega3OutcomePathologicPatternPersonsPharmaceutical PreparationsPhasePhosphatidesPhospholipidsPhysical FunctionPhysical activityPlacebosPlasmaPlasma SerumPost-MenopausePost-menopausal PeriodPostmenopausal PeriodPostmenopausePreventionProbabilityProductionProtonsRandomized, Controlled TrialsRecommendationReduced mobilityReduction in mobilityReportingResistanceRespirationReticuloendothelial System, Serum, PlasmaRiskRodent ModelRoleSham TreatmentSideSkeletal MuscleSourceSpecific qualifier valueSpecifiedSpillageSupplementationTestingTherapeuticThinnessTissuesTriacylglycerolTriglyceridesTruncal obesityVegetable OilsVoluntary MuscleWomanadulthoodafter menopauseage associatedage associated declineage correlatedage dependentage dependent declineage linkedage relatedage related declineage specificagescardiometaboliccardiometabolismcis-9-Octadecenoic Acidcompare to controlcomparison controldecline with agedevelopmentaldietarydietary approachdietsdisease riskdisorder riskdrug/agentelectron transferepidemiologic datafall riskfollowing menopausehealth dataimprovedinnovateinnovationinnovativeinsulin resistantinsulin tolerancelinoleateslong chain fatty acidlong-term studylongitudinal outcome studiesmitochondrialmitochondrial dysfunctionmortalitymuscle breakdownmuscle bulkmuscle degradationmuscle deteriorationmuscle formmuscle lossmuscle massmuscle strengthmuscle wastingmuscularn-3 Fatty Acidsn-3 PUFAnutrient requirementnutrition biomarkerolder adultolder adulthoodolder groupsolder individualsolder menolder personolder womenomega-3omega-3sorthopedic freezingpast menopausepeerphase 2 trialphase II trialphysical impairmentpost-menopausalpostmenopausalpostmenopausal statuspreventpreventingprimary outcomeprotective effectprotein intakerandomized control trialresistance exerciseresistance trainingresistantrespiratory mechanismsarcopeniasarcopenicscaffoldscaffoldingsham therapyskeletal muscle atrophyskeletal muscle breakdownskeletal muscle lossskeletal muscle protein lossskeletal muscle wastingsocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentvisceral obesity
Description preview
Sarcopenia, the age-related loss of skeletal muscle mass and function, predicts for morbidity, mortality and
excessive healthcare costs. Other than exercise, lifestyle therapies for slowing the progression of sarcopenia
in older men and women remain elusive. Mitochondrial dysfunction is a common mechanistic link between
aging and many pathological…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click